Oncology expertise

Oncology trial operations by indication and milestone

Lampgen supports sponsors and CROs across solid tumor and hematologic oncology studies. Match the role to the phase, protocol, site workload, and decisions your team needs someone to own.

Define the work around your next milestone

Use these assignment examples to decide where you need coverage, coordination, or study-level ownership.

Early phase · Solid tumors and blood cancers · CTM and CRA

Startup and cohort expansion

A CTM or Clinical Study Manager can coordinate activation, cohort timelines, and CRO and vendor handoffs. A CRA can review protocol-specific site readiness and follow up on training, essential documents, and open actions.

Explore CTM support →
Study conduct · Multisite oncology · Lead CRA

Monitoring across multiple sites

A Lead CRA can coordinate visit coverage, review monitoring reports for consistency, and surface recurring deviations and overdue actions for the study team to resolve.

See a SIGNAL™ monitoring example →
Phase Ib/II example · Multiple myeloma · Senior CRA

Database-lock preparation

A Senior CRA can follow open queries, deviations, and essential documents through resolution within the monitoring assignment. A CTM can coordinate issues that require a study-level decision or action across functions.

Explore oncology CRA staffing →

Oncology Trial Operations by Indication

Find your indication, open a handoff checklist for your study setting, and scope the oncology staffing or oversight your team needs.

Solid tumors

Bladder cancer

When a cystoscopy moves or pathology comes back late, who owns the next step?

Study settings and handoff checklists
BCG-unresponsive non-muscle-invasive bladder cancer

A referral can stall when prior BCG instillations are documented in outside urology records or the pathology record is incomplete.

CRA scope
Check that the assigned site can produce the BCG dates, pathology, and required cystoscopy or cytology records for study-team review.
CTM or Clinical Study Manager scope
Confirm who requests outside records and when an unresolved referral goes to the eligibility team.
Handoff checklist

Prior BCG and pathology records

Owner to confirm
Site urology coordinator to the designated eligibility reviewer
Window to track
Before the protocol’s screening decision
Evidence to have ready
Dated BCG administration history and applicable pathology report
When to escalate
A prior course or required pathology record is missing near the screening deadline.
Perioperative muscle-invasive bladder cancer

A moved cystectomy can change when surgical pathology, postoperative assessments, or a planned return to oncology can occur.

CRA scope
Reconcile planned and actual procedure dates and follow up on the source reports needed for the next assessment.
CTM or Clinical Study Manager scope
Track the surgery-to-oncology handoff and bring schedule conflicts to the sponsor’s designated decision owner.
Handoff checklist

Cystectomy to postoperative oncology follow-up

Owner to confirm
Surgical coordinator to the oncology study team
Window to track
From surgery scheduling through the next protocol-defined visit
Evidence to have ready
Actual surgery date, pathology status, and follow-up appointment
When to escalate
The surgery or pathology timeline puts the next study window at risk.
Bladder preservation in muscle-invasive disease

Urology, radiation oncology, and imaging can each use different schedules for procedures that support one protocol assessment.

CRA scope
Check required cystoscopy, biopsy, and imaging records against the visit plan and follow up on missing evidence.
CTM or Clinical Study Manager scope
Confirm procedure capacity and who coordinates rebooking when treatment or assessment dates change.
Handoff checklist

Multidisciplinary assessment packet

Owner to confirm
Site coordinator with urology, radiation oncology, and imaging contacts
Window to track
At the protocol-defined response assessment
Evidence to have ready
Required procedure, pathology, and imaging reports with dates
When to escalate
A required procedure is unbooked or a report is unavailable by the assessment review.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Compare repeat procedure-window misses, incomplete assessment packets, and surgery-to-oncology handoff delays across sites.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Urothelial cancer may remain outside the bladder’s muscle layer, invade that muscle, or spread beyond the bladder. Each setting leads to a different trial pathway.
Where trials get complex
A bladder-preservation study may depend on timed cystoscopy and biopsy. A perioperative study may depend on surgery dates, surgical pathology, and the handoff back to oncology.
What to scope early
Confirm who tracks procedure windows, transmits pathology, and follows up when the surgical or urology schedule changes.

Breast cancer

Is the right receptor result or surgical pathology report available when the study needs it?

Study settings and handoff checklists
ESR1-selected advanced or metastatic disease

A molecular result can arrive without the dated endocrine therapy history needed to determine whether a patient fits the cohort.

CRA scope
Follow up on the required ESR1 report, specimen dates, prior regimens, and progression documentation at assigned sites.
CTM or Clinical Study Manager scope
Agree on local and central testing responsibilities and the escalation path for inconclusive or delayed results.
Handoff checklist

Molecular result and endocrine history

Owner to confirm
Site oncology coordinator to the designated eligibility reviewer
Window to track
Before cohort assignment
Evidence to have ready
Protocol-accepted assay report and dated prior-treatment history
When to escalate
The assay or treatment record needed for review is incomplete.
HER2-selected breast cancer

An archived report may use a different specimen, assay, or scoring convention than the one a particular HER2-selected protocol accepts.

CRA scope
Check that the submitted report identifies the specimen, method, and required score or confirmatory test.
CTM or Clinical Study Manager scope
Set ownership for retrieval of blocks or slides, central testing where required, and resolution of discordant reports.
Handoff checklist

HER2 specimen to accepted test result

Owner to confirm
Site pathology contact to the local or central lab and eligibility team
Window to track
Early enough to complete protocol-required review before enrollment
Evidence to have ready
Specimen identifiers, assay method, and signed result
When to escalate
Tissue is inadequate or local and central results require review.
Early triple-negative breast cancer around surgery

A change in preoperative treatment or surgery timing can disrupt collection of the resection specimen and pathologic response data.

CRA scope
Verify dates and required surgical pathology fields against the site’s source records.
CTM or Clinical Study Manager scope
Coordinate the treatment-to-surgery calendar and assign ownership for the pathology package and any review queries.
Handoff checklist

Surgery to pathologic response review

Owner to confirm
Breast surgery and pathology to the oncology study coordinator
Window to track
From the surgical booking through the protocol’s pathology review
Evidence to have ready
Dated operative record and required resection pathology fields
When to escalate
The surgery moves or the pathology package omits an endpoint field.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Compare assay rework, missing prior-treatment records, and late surgical pathology across sites.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Hormone receptor status and HER2 status distinguish biologically and clinically different breast cancer groups, including triple-negative disease.
Where trials get complex
When enrollment depends on receptor status, the protocol may specify the specimen, assay, and whether local or central testing determines eligibility. In preoperative studies, surgery and pathology may also drive endpoint timing.
What to scope early
Define which result determines eligibility and how sites resolve discordant reports or delayed surgical pathology.

Colorectal cancer

Can your sites complete the specimen and assessment handoffs before the next study decision?

Read the colorectal cancer trial operations guide

Study settings and handoff checklists
Postoperative ctDNA studies

Resected tissue and postoperative blood may reach the central lab separately. A missing or unusable specimen can delay the result needed for the next study decision.

CRA scope
Check the surgery date, collection date, shipping record, and lab receipt against the protocol and lab manual.
CTM or Clinical Study Manager scope
Track pending results against the enrollment or randomization milestone and coordinate site and lab follow-up.
Handoff checklist

Surgery and specimen collection to central ctDNA review

Owner to confirm
Site study coordinator and pathology to the central lab
Window to track
At the protocol-defined postoperative draw and before the next study decision
Evidence to have ready
Resection date, tissue and blood shipment records, and lab status
When to escalate
A specimen is delayed, rejected, or still unaccounted for near the decision date.
Molecularly selected metastatic disease

A cohort may require a particular mismatch repair or molecular result and a specific prior-treatment history. Those records often reach the site through different channels.

CRA scope
Follow up on the accepted molecular report and dated treatment and progression records.
CTM or Clinical Study Manager scope
Set the review route for the qualifying result and align referrals with assay and cohort availability.
Handoff checklist

Molecular eligibility and treatment history

Owner to confirm
Site research coordinator to the designated screening reviewer
Window to track
Before enrollment in the selected cohort
Evidence to have ready
Required assay report plus documented prior lines and progression
When to escalate
A sample or result is missing or cannot be matched to the protocol’s test requirement.
Locally advanced rectal cancer and organ preservation

Restaging may bring MRI, endoscopy, and clinical exam together. One delayed component can leave the study team with an incomplete review packet.

CRA scope
Reconcile the required restaging assessments with their source dates and follow up on missed components.
CTM or Clinical Study Manager scope
Coordinate the restaging calendar across imaging, endoscopy, and the surgical team under the protocol.
Handoff checklist

Restaging evidence to multidisciplinary review

Owner to confirm
Site coordinator with imaging, endoscopy, and surgical contacts
Window to track
At the protocol’s post-treatment assessment
Evidence to have ready
Required dated imaging, endoscopy, and clinical assessment records
When to escalate
An assessment is missing or a follow-up window is at risk.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Distinguish late postoperative draws, insufficient tissue, courier exceptions, and lab turnaround before deciding where to intervene.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Colorectal cancer starts in the colon or rectum. A study after resection asks a different question from one enrolling people with measurable metastatic disease.
Where trials get complex
Metastatic cohorts may require a defined mismatch repair or molecular profile and prior treatment history. A postoperative study that uses circulating tumor DNA adds blood-draw windows tied to surgery.
What to scope early
Map the required biomarker result, surgery date, and specimen collection to the screening and follow-up schedule.

Cutaneous melanoma

Which pathology, prior therapy, or imaging record determines the next step for your cohort?

Study settings and handoff checklists
Resected melanoma and adjuvant studies

Operative records, nodal pathology, and baseline imaging may sit with separate teams while enrollment is tied to the resection date.

CRA scope
Reconcile resection and staging evidence at assigned sites and follow up on missing reports.
CTM or Clinical Study Manager scope
Agree on who tracks the post-resection window and receives a decision request when the packet is incomplete.
Handoff checklist

Surgical and staging packet

Owner to confirm
Surgical oncology and pathology to the enrolling study team
Window to track
Within the protocol’s post-resection screening period
Evidence to have ready
Dated operative and pathology reports with any required baseline imaging
When to escalate
Staging evidence is incomplete close to the enrollment window.
BRAF-selected unresectable or metastatic melanoma

A referral needs both an accepted BRAF result and the correct history of prior systemic therapy for the specific protocol.

CRA scope
Check the report source and reconcile documented prior therapy and progression at assigned sites.
CTM or Clinical Study Manager scope
Define who retrieves tissue or external records and how the team routes a discordant result for review.
Handoff checklist

BRAF result and prior systemic therapy

Owner to confirm
Site pathology and oncology contacts to the screening reviewer
Window to track
Before cohort allocation
Evidence to have ready
Protocol-accepted molecular report and dated treatment history
When to escalate
The mutation result or prior therapy record is unavailable by review.
Melanoma with a brain metastasis cohort

Brain imaging, prior CNS-directed therapy, and systemic assessments can follow different schedules and require separate review.

CRA scope
Check the protocol-required CNS source records and image transfers alongside systemic assessments.
CTM or Clinical Study Manager scope
Coordinate imaging windows and clarify which team resolves discrepancies in CNS records.
Handoff checklist

CNS and systemic assessment records

Owner to confirm
Neuroradiology and site research staff to the protocol’s reviewing team
Window to track
At baseline and scheduled assessment points
Evidence to have ready
Dated brain images and reports, prior CNS therapy records, and applicable systemic assessment
When to escalate
A required scan or history is unavailable or outside the assessment window.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Compare incomplete staging packets, delayed molecular reports, and missing CNS imaging by site and cause.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Cutaneous melanoma arises from pigment-producing cells in the skin. Trial cohorts can differ by stage, BRAF status, and prior systemic therapy.
Where trials get complex
In advanced-disease studies, the sequence of prior immunotherapy or targeted treatment can matter for eligibility. A protocol with a brain metastasis cohort may also specify separate imaging and eligibility requirements.
What to scope early
Confirm how sites document prior treatment and progression, and who reconciles systemic and brain imaging when the protocol requires both.

Non-small cell lung cancer (NSCLC)

Will a qualifying tissue or molecular result arrive before the planned study start?

Read the NSCLC trial operations guide

Study settings and handoff checklists
Biomarker-selected advanced NSCLC

A local report can be informative while the protocol still requires a specific specimen, assay, or centrally confirmed result.

CRA scope
Track the site’s specimen and test records and reconcile prior targeted-therapy dates where the cohort requires them.
CTM or Clinical Study Manager scope
Agree on tissue routing, turnaround expectations, and the escalation point for an inadequate specimen or pending result.
Handoff checklist

Tissue and qualifying molecular result

Owner to confirm
Site pathology and molecular lab to the study’s eligibility reviewer
Window to track
Within the protocol screening window
Evidence to have ready
Specimen status, accepted assay result, and applicable prior treatment record
When to escalate
A sample is inadequate or a result remains pending near the planned start.
Resectable NSCLC around surgery

Restaging, thoracic surgery booking, and surgical pathology have to move together when the preoperative course changes.

CRA scope
Check the required treatment, imaging, surgery, and pathology dates against the site’s source.
CTM or Clinical Study Manager scope
Coordinate the handoff from medical oncology to thoracic surgery and back, with a sponsor escalation route for delays.
Handoff checklist

Preoperative treatment to resection and pathology

Owner to confirm
Site oncology coordinator and thoracic surgery to the study team
Window to track
Between protocol-defined preoperative and postoperative milestones
Evidence to have ready
Restaging status, actual resection date, and required surgical pathology
When to escalate
A booking change or incomplete pathology threatens the next assessment.
Unresectable stage III NSCLC after chemoradiation

The completion date, post-treatment assessment, and any qualifying biomarker result can be held by separate departments.

CRA scope
Reconcile chemotherapy and radiation completion dates and follow up on required scans or test results.
CTM or Clinical Study Manager scope
Assign owners for the end-of-treatment packet and bring missing information to the study team before the next review.
Handoff checklist

Chemoradiation completion to study eligibility review

Owner to confirm
Radiation and medical oncology to the enrolling coordinator
Window to track
During the protocol’s post-treatment screening period
Evidence to have ready
Dated treatment records, required assessment, and any qualifying molecular report
When to escalate
A treatment date or assessment cannot be confirmed within the review window.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Separate tissue inadequacy, lab turnaround, and handoff delays across sites, including recurring misses after surgery or chemoradiation.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
NSCLC includes adenocarcinoma, squamous cell carcinoma, and other subtypes. Histology, disease stage, and molecular profile can shape which cohort fits.
Where trials get complex
A biomarker-selected study can depend on tissue availability, the required assay, and a usable report before the screening window closes. Prior treatment may also determine cohort eligibility.
What to scope early
Agree on how sites confirm tissue adequacy, track local or central results, and escalate a pending result before the planned start.

Epithelial ovarian cancer

Can the team reconstruct prior platinum exposure, progression dates, and the biomarker evidence this cohort needs?

Study settings and handoff checklists
Platinum-resistant recurrent disease

The interval between prior platinum and progression can depend on dates scattered across infusion, imaging, and external records.

CRA scope
Reconcile prior platinum dates, progression evidence, and any required biomarker result, such as folate receptor alpha status when specified.
CTM or Clinical Study Manager scope
Define who requests external treatment records and how discrepancies reach the designated eligibility reviewer.
Handoff checklist

Prior platinum and progression documentation

Owner to confirm
Site oncology coordinator to the study eligibility team
Window to track
Before the recurrent cohort is assigned
Evidence to have ready
Dated platinum course, progression record, and protocol-required test report
When to escalate
Dates conflict or the qualifying result is unavailable near screening close.
Biomarker-selected first-line maintenance

The post-platinum response assessment and a required BRCA or homologous recombination deficiency report may mature on different timelines.

CRA scope
Check that prior response, completion dates, and assay evidence are documented against the maintenance screening window.
CTM or Clinical Study Manager scope
Coordinate specimen retrieval and test tracking with the decision to enter maintenance screening.
Handoff checklist

Post-platinum response and qualifying biomarker

Owner to confirm
Medical oncology and pathology to the enrolling study team
Window to track
Before maintenance randomization or study start
Evidence to have ready
Dated treatment and response records and the protocol-accepted result
When to escalate
Response review or testing remains open near the maintenance window.
Neoadjuvant treatment and interval debulking

Surgery scheduling and postoperative pathology can change the sequence of protocol treatment and assessments.

CRA scope
Verify cycle, surgery, and recovery assessment dates and follow up on the required operative and pathology records.
CTM or Clinical Study Manager scope
Coordinate medical and gynecologic oncology handoffs and identify who confirms the updated timeline.
Handoff checklist

Neoadjuvant cycles to interval surgery and follow-up

Owner to confirm
Site oncology and gynecologic surgery coordinators
Window to track
Between the last planned preoperative cycle and the next protocol milestone
Evidence to have ready
Cycle dates, operative report, pathology status, and planned follow-up
When to escalate
Surgery or the postoperative records fall behind the agreed study window.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Review recurring prior-line classification queries, delayed assay results, and surgery-to-oncology documentation gaps.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Epithelial ovarian, fallopian tube, and primary peritoneal cancers are often studied together. Histology and prior therapy still matter when defining the cohort.
Where trials get complex
In recurrent disease, the timing of progression relative to prior platinum therapy can determine eligibility. A biomarker-selected maintenance study can also depend on access to an adequate specimen and the protocol-specified test.
What to scope early
Decide how sites reconstruct prior platinum dates, document progression, and track any required BRCA or homologous recombination deficiency result.

Pancreatic adenocarcinoma

Who connects restaging, surgical review, and the study calendar when the operative plan changes?

Study settings and handoff checklists
Borderline resectable pancreatic adenocarcinoma

A restaging scan and surgical review can change the planned operative path after preoperative treatment.

CRA scope
Check the dated scan, surgical assessment, and treatment milestones required by the protocol.
CTM or Clinical Study Manager scope
Set responsibility for cross-team scheduling and for notifying the sponsor when the operative plan moves.
Handoff checklist

Restaging imaging to surgical review

Owner to confirm
Radiology and the site coordinator to surgical oncology
Window to track
At the protocol’s resectability assessment
Evidence to have ready
Restaging images or report, documented surgical review, and updated operative plan
When to escalate
The review or planned surgery moves outside the study team’s agreed timeline.
First-line metastatic pancreatic adenocarcinoma

Outside diagnostic records and baseline imaging may still be pending while the site is working toward the first treatment date.

CRA scope
Confirm the required baseline scan, diagnostic source, and prior-treatment information are accessible at assigned sites.
CTM or Clinical Study Manager scope
Coordinate the referral-to-screening handoff and assign a decision owner for unresolved baseline requirements.
Handoff checklist

Referral records to baseline assessment

Owner to confirm
Referring team and site research coordinator to the eligibility reviewer
Window to track
Before protocol enrollment or first dose
Evidence to have ready
Diagnostic documentation, protocol-required baseline imaging, and prior-treatment record
When to escalate
An outside record or required scan remains unavailable at review.
Germline BRCA-selected maintenance

A qualifying germline result and evidence of disease status on prior platinum may come from different providers.

CRA scope
Check the documented testing method, treatment dates, and required response or progression assessment.
CTM or Clinical Study Manager scope
Align the testing and chart-retrieval plan to the maintenance screening timeline.
Handoff checklist

Germline report and prior platinum evidence

Owner to confirm
Genetics lab and medical oncology to the protocol reviewer
Window to track
Before the maintenance eligibility decision
Evidence to have ready
Protocol-accepted germline result, platinum history, and disease assessment
When to escalate
The report or assessment needed to complete the review is missing.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Separate restaging-to-surgery delays, missing baseline records, and germline testing turnaround by site.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Pancreatic adenocarcinoma is an exocrine cancer. Resectable, borderline resectable, locally advanced, and metastatic settings raise different study questions.
Where trials get complex
In a study around surgery, imaging review and surgical assessment can determine whether a patient fits the cohort. Therapy, restaging, and surgery must then stay aligned with protocol windows.
What to scope early
Identify who confirms resectability and how radiology, surgical oncology, and the study team communicate changes in the operative plan.

Prostate cancer

Are the treatment history, scan dates, and eligibility evidence aligned for the cohort you’re enrolling?

Study settings and handoff checklists
Metastatic hormone-sensitive prostate cancer

Baseline imaging and the start of androgen deprivation may be documented in different settings while the screening window is running.

CRA scope
Reconcile prior and current hormonal therapy dates with imaging and baseline documentation at assigned sites.
CTM or Clinical Study Manager scope
Set ownership for external scan retrieval and for review of prior treatment against the protocol.
Handoff checklist

Hormonal treatment history and baseline imaging

Owner to confirm
Referring urology or oncology team to the study coordinator
Window to track
Before enrollment or randomization as specified by the protocol
Evidence to have ready
Treatment start dates, baseline scan reports, and required disease-status documentation
When to escalate
A missing treatment date or scan prevents a timely review.
Metastatic castration-resistant prostate cancer

PSA, imaging, and clinical events may occur on separate calendars. A protocol may require specific evidence of progression and prior therapy.

CRA scope
Reconcile dated PSA, imaging, and treatment records and follow up on missing source used for endpoint review.
CTM or Clinical Study Manager scope
Assign ownership for imaging transfers and route conflicting or late assessments to the appropriate reviewer.
Handoff checklist

Progression evidence to study review

Owner to confirm
Site research and imaging teams to the designated endpoint reviewer
Window to track
At baseline and each required progression assessment
Evidence to have ready
Dated scans, required labs, and supporting treatment history
When to escalate
An endpoint component is missing or outside its assessment window.
PSMA-selected radioligand studies

The qualifying PET result and a nuclear medicine treatment slot can depend on different teams and lead times.

CRA scope
Check required PET source, review status, and treatment administration records against the protocol.
CTM or Clinical Study Manager scope
Coordinate the imaging-to-treatment handoff and clarify escalation for a delayed read or treatment slot.
Handoff checklist

PSMA PET review to nuclear medicine scheduling

Owner to confirm
Imaging and nuclear medicine coordinators to the study team
Window to track
Before allocation and before the planned treatment visit
Evidence to have ready
Required PET report or central review and confirmed treatment appointment
When to escalate
Review or scheduling falls behind the protocol timeline.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Compare recurring imaging-upload delays, missing hormone-treatment records, and scheduling gaps between PET and nuclear medicine.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Advanced prostate cancer studies distinguish hormone-sensitive disease from disease that progresses despite castrate testosterone levels.
Where trials get complex
When a study enrolls patients with bone metastases, imaging, prostate-specific antigen (PSA), and symptoms may be assessed on different schedules. The protocol defines which findings count toward progression.
What to scope early
Align bone imaging and lab windows, and agree on how the team reconciles missing or conflicting assessments before endpoint review.

Soft tissue sarcoma

Can your sites identify the right subtype and get pathology or molecular confirmation before enrollment?

Read the soft tissue sarcoma trial operations guide

Study settings and handoff checklists
Histology-selected advanced soft tissue sarcoma

A rare-subtype referral can arrive without the slides or blocks needed for protocol-required central confirmation.

CRA scope
Check retrieval, dispatch, receipt, and review status of the required pathology material at assigned sites.
CTM or Clinical Study Manager scope
Confirm the referral route, reviewing pathologist, and escalation owner when outside material is delayed.
Handoff checklist

Outside pathology to subtype confirmation

Owner to confirm
Referring pathology team to the study’s designated reviewer
Window to track
Before subtype-specific enrollment
Evidence to have ready
Required slides or blocks, specimen receipt, and pathology determination
When to escalate
The reviewing team lacks the specimen or report needed for the decision.
Localized high-risk sarcoma around surgery

A shift in preoperative therapy or resection can disrupt the specimen plan and postoperative assessment schedule.

CRA scope
Reconcile dates and check that specimen and operative records required by the protocol reach the study team.
CTM or Clinical Study Manager scope
Coordinate surgery, pathology, and oncology dependencies and route schedule changes for sponsor review.
Handoff checklist

Resection to pathology and follow-up

Owner to confirm
Surgical coordinator and pathology to the site oncology team
Window to track
From the planned resection through the required follow-up assessment
Evidence to have ready
Actual procedure date, specimen record, and protocol-required pathology
When to escalate
The operative plan changes or the endpoint packet is incomplete.
HLA- and antigen-selected synovial sarcoma

HLA typing and tumor antigen expression may be confirmed through separate testing workflows before a cell therapy study can move forward.

CRA scope
Check that both required reports are traceable to the site’s source and follow up on pending tests.
CTM or Clinical Study Manager scope
Align the dual-testing timeline with referral and study scheduling, and assign a reviewer for discordant or delayed results.
Handoff checklist

HLA and tumor antigen results to eligibility review

Owner to confirm
Testing labs and site coordinator to the designated study reviewer
Window to track
Before the next protocol-defined cell therapy milestone
Evidence to have ready
Both required test reports, specimen tracking, and review status
When to escalate
One result is missing, unusable, or late enough to affect the schedule.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Compare delays from referral, tissue retrieval, central pathology, and dual-marker testing to see which handoffs recur across sites.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Soft tissue sarcoma covers multiple rare cancers with distinct histologies and patterns of behavior.
Where trials get complex
A subtype-specific study can draw from a small referral pool. If central pathology confirmation is required, transfer of slides or blocks can become a key screening dependency.
What to scope early
Confirm which sites see the relevant subtype, how specimens reach the reviewing pathologist, and who tracks the result before enrollment.

Uveal melanoma

Who coordinates ocular history, liver imaging, and any qualifying test before the next study decision?

Study settings and handoff checklists
Localized uveal melanoma and eye-sparing studies

Baseline ocular assessment and follow-up can be done in ophthalmology while the research team needs a complete, dated record.

CRA scope
Check that the protocol-required ocular imaging and exam records are available and consistently dated.
CTM or Clinical Study Manager scope
Agree who books ophthalmic follow-up and who receives a missing-assessment alert.
Handoff checklist

Ocular assessment to study follow-up

Owner to confirm
Ocular oncology and ophthalmic imaging to the site research team
Window to track
At baseline and each protocol-defined ocular assessment
Evidence to have ready
Required dated eye examination and imaging records
When to escalate
A required assessment cannot be booked or the report is unavailable.
HLA-selected metastatic uveal melanoma

A qualifying HLA report, prior treatment history, and baseline imaging may need to be assembled by teams at different institutions.

CRA scope
Follow up on the required HLA report, imaging records, and applicable prior liver-directed or systemic therapy.
CTM or Clinical Study Manager scope
Clarify who owns the ocular-to-medical-oncology referral and who reviews the assembled screening packet.
Handoff checklist

HLA result and metastatic baseline evidence

Owner to confirm
Site coordinator with the testing lab and imaging team
Window to track
Before the study’s eligibility decision
Evidence to have ready
Protocol-accepted HLA result, dated imaging, and required therapy history
When to escalate
A qualifying result or baseline image cannot be reviewed on schedule.
Liver-directed metastatic uveal melanoma

Imaging review and interventional procedure capacity can determine when a liver-directed study visit can happen.

CRA scope
Check required baseline scans, procedural documentation, and scheduled post-procedure assessments.
CTM or Clinical Study Manager scope
Coordinate the imaging, interventional radiology, and oncology calendar and define how delays are escalated.
Handoff checklist

Liver imaging review to procedure and follow-up

Owner to confirm
Interventional radiology coordinator and site oncology team
Window to track
From procedure booking through the next required study assessment
Evidence to have ready
Required imaging, procedure record, and follow-up schedule
When to escalate
A procedure date changes or the post-procedure evidence is incomplete.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Compare missing ocular records, HLA testing turnaround, and liver imaging or procedure documentation gaps across sites.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Uveal melanoma starts in the pigmented tissues inside the eye and is biologically distinct from cutaneous melanoma. The liver is a common site of metastatic spread.
Where trials get complex
Metastatic studies may need coordination between ocular oncology and medical oncology, consistent liver imaging, and, in some protocols, HLA typing.
What to scope early
Assign ownership for referral records, baseline liver imaging, and any required HLA result before the eligibility review.

Blood cancers

Acute myeloid leukemia (AML)

Can your sites complete marrow and molecular handoffs before the study’s screening window closes?

Study settings and handoff checklists
Newly diagnosed, molecularly selected AML

Marrow collection, local diagnostics, and a qualifying molecular result may have to fit within a short enrollment window.

CRA scope
Check collection, shipment, and result availability for the required specimen and assay at assigned sites.
CTM or Clinical Study Manager scope
Set the lab turnaround and escalation route with the sponsor and site teams before enrollment opens.
Handoff checklist

Marrow and molecular result to eligibility review

Owner to confirm
Site hematology and the molecular lab to the designated reviewer
Window to track
Before the protocol’s enrollment or treatment-start decision
Evidence to have ready
Collection and receipt records and the qualifying molecular report
When to escalate
The sample or report is missing as the screening window approaches.
Relapsed or refractory AML

Prior regimens, response, and relapse dates can span multiple providers. Missing history can delay review of a time-sensitive referral.

CRA scope
Reconcile dated treatment and disease-assessment records and flag missing prior marrow or molecular reports.
CTM or Clinical Study Manager scope
Agree who retrieves outside records and how a missing or conflicting document reaches the study reviewer.
Handoff checklist

Prior treatment and relapse evidence

Owner to confirm
Referring hematology team to the enrolling site coordinator
Window to track
Before the relapsed or refractory cohort is assigned
Evidence to have ready
Dated prior regimens, response or relapse record, and any required assay
When to escalate
Prior lines or disease status cannot be documented by review.
Remission, maintenance, or residual disease assessment

Marrow assessment, blood count recovery, and any measurable residual disease result can become available at different times.

CRA scope
Reconcile the protocol-required specimen and response records against the assessment calendar.
CTM or Clinical Study Manager scope
Assign owners for pending results and agree who determines whether an incomplete packet needs a study decision.
Handoff checklist

Remission assessment to maintenance or endpoint review

Owner to confirm
Site hematology coordinator and lab to the study review team
Window to track
At the protocol-defined remission or maintenance milestone
Evidence to have ready
Dated marrow and blood count records and any required residual disease report
When to escalate
A required result is unavailable or the collection is outside its window.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Compare recurring marrow shipment exceptions, late molecular results, and incomplete remission-assessment packets across sites.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
AML is an acute cancer of myeloid blood-forming cells. Disease status and molecular findings can define different cohorts.
Where trials get complex
Marrow collection, local testing, and any required molecular confirmation may need to occur within a short screening window. A mutation-selected cohort adds a dependency on when the qualifying result is available.
What to scope early
Map marrow collection and lab turnaround, and agree who escalates missing results when the treatment start is approaching.

Diffuse large B-cell lymphoma (DLBCL)

Who owns the pathology, PET/CT, and treatment-transition evidence your lymphoma trial needs?

Study settings and handoff checklists
Frontline DLBCL

Biopsy confirmation, baseline PET/CT, and risk documentation can come from different teams before the first treatment visit.

CRA scope
Check protocol-required pathology and imaging records and follow up on missing baseline fields.
CTM or Clinical Study Manager scope
Align referral and imaging timelines and identify who reviews an incomplete staging packet.
Handoff checklist

Pathology and staging to frontline enrollment

Owner to confirm
Site pathology and imaging to the lymphoma study coordinator
Window to track
Before the protocol’s frontline enrollment decision
Evidence to have ready
Signed pathology, baseline PET/CT and required staging records
When to escalate
Pathology or baseline imaging cannot be reviewed before the planned start.
Relapsed or refractory DLBCL with transplant intent

Salvage response imaging and transplant referral may advance on separate calendars. A delayed scan can hold up the next decision.

CRA scope
Check prior regimen and response records and track transfer of required pre- or post-salvage images.
CTM or Clinical Study Manager scope
Coordinate the PET/CT and transplant review schedule and route unresolved dependencies to the study team.
Handoff checklist

Salvage response to transplant review

Owner to confirm
Lymphoma and transplant coordinators with imaging
Window to track
At the protocol’s post-salvage decision point
Evidence to have ready
Prior-treatment dates, required response imaging, and documented referral status
When to escalate
A required scan or response report is missing ahead of review.
CAR T-cell studies in relapsed or refractory DLBCL

Leukapheresis, manufacturing, any bridging treatment, and infusion each have different owners and dates to reconcile.

CRA scope
Check source and tracking records for the protocol-defined cell collection and treatment milestones at assigned sites.
CTM or Clinical Study Manager scope
Agree who maintains the site-to-manufacturer timeline and how a collection, release, or infusion change reaches the sponsor.
Handoff checklist

Cell collection to manufacturing and infusion

Owner to confirm
Cell therapy site coordinator and manufacturing contact to the study team
Window to track
At each protocol-defined transition
Evidence to have ready
Dated collection, applicable bridging therapy, and product or infusion records
When to escalate
A collection, release, or infusion change puts the study timeline at risk.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Compare recurring pathology and image-transfer delays and trace open actions around salvage or cell therapy transitions.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
DLBCL is an aggressive B-cell lymphoma. Newly diagnosed and relapsed or refractory studies enroll different populations.
Where trials get complex
Eligibility can depend on pathology and the history of prior regimens. Where PET/CT informs response, scan timing and image transfer affect when reviewers can assess an endpoint.
What to scope early
Verify the pathology and treatment-history handoffs, then assign responsibility for baseline and follow-up imaging uploads.

Multiple myeloma

Can your sites reconcile prior lines and response assessments before the next transplant, cohort, or endpoint decision?

Read the multiple myeloma trial operations guide

Study settings and handoff checklists
Newly diagnosed, transplant-eligible myeloma

Induction, stem-cell collection, transplant, and consolidation may be documented by different teams.

CRA scope
Reconcile required induction dates, response evidence, and transplant records at assigned sites.
CTM or Clinical Study Manager scope
Coordinate the treatment-to-transplant calendar and set responsibility for communicating changes to the sponsor.
Handoff checklist

Induction response to transplant planning

Owner to confirm
Myeloma and transplant coordinators to the study team
Window to track
Between protocol-defined induction and transplant milestones
Evidence to have ready
Treatment dates, required response records, and transplant schedule
When to escalate
A missing response assessment or changed transplant date affects the next milestone.
Relapsed or refractory multiple myeloma

Prior lines and drug-class exposures can span multiple institutions. Records may require reconciliation before the sponsor can review cohort fit.

CRA scope
Check dated prior regimens, class exposure, and response or progression evidence against the study’s documentation needs.
CTM or Clinical Study Manager scope
Assign ownership for external records and route unresolved prior-line questions to the designated reviewer.
Handoff checklist

Prior-line and drug-class history

Owner to confirm
Site coordinator and referring practices to the eligibility reviewer
Window to track
Before cohort allocation
Evidence to have ready
Dated regimens, applicable class exposure, and response or progression records
When to escalate
A prior line or drug-class exposure remains undocumented.
Measurable residual disease and response depth

Marrow sampling and serum or urine assessments may fall on separate calendars. A delayed specimen or report can leave an incomplete response packet.

CRA scope
Track the protocol-required specimen, collection dates, and reports and reconcile the source with data entry.
CTM or Clinical Study Manager scope
Agree who follows lab status and who escalates incomplete results before an endpoint or maintenance review.
Handoff checklist

Response specimens to lab and endpoint review

Owner to confirm
Site research coordinator and central lab to the study review team
Window to track
At protocol-defined response or maintenance assessment points
Evidence to have ready
Required marrow and lab records, receipt status, and dated reports
When to escalate
A required sample is missed, unusable, or pending near review.
When issues repeat across sites

A Lead CRA can help coordinate recurring findings and raise decisions to your study team. For a defined SIGNAL Managed Monitoring scope, Lampgen would discuss how to review these patterns with you.

Group recurring prior-line discrepancies, missed transplant handoffs, and late marrow or lab results by site and cause.

Explore SIGNAL Managed Monitoring
Disease snapshot and sources
Disease snapshot
Multiple myeloma is a cancer of plasma cells. Trial cohorts can differ by prior lines of therapy, treatment response, and transplant eligibility.
Where trials get complex
Response can require coordinated lab results and marrow assessments. When the protocol includes measurable residual disease, the specimen, assessment window, and lab result all need to line up.
What to scope early
Reconcile prior regimens and plan serum, urine, and marrow collection around the protocol’s response calendar.

Already working with a CRO?

Lampgen can help scope a CRA, Lead CRA, CTM, or Clinical Study Manager for a defined assignment alongside your sponsor or CRO team. Bring the role or workload gap, affected sites or region, and target start. We’ll discuss who directs the work and what an incoming professional needs for the handoff.

Discuss your staffing need

Selected oncology engagements

See the responsibilities Lampgen’s founder owned on a hematologic oncology monitoring assignment and a global solid tumor study.

Plan for the protocol’s operating demands

The founder’s operating experience includes biomarker-led studies, immuno-oncology, targeted therapies, and combination programs. The protocol and its handoffs shape the staffing brief.

Biomarker screening and specimen workflows

Define who owns screening, sample handoffs, result review, and follow-up when something is missing.

Read the workflow guide →

Evaluate oncology experience

Ask about phase, treatment model, site responsibilities, and what the candidate personally owned.

Read the staffing guide →

FDA Oncology Approval Tracker

Review approved uses, FDA source records, and the operational questions selected decisions raise for study teams.

Open the approval tracker →

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?